About Us

For the first time, precisely targeting every protein could be within reach. Our team is making that happen.

Neomorph is an old genetic concept that names something entirely new: a structure or function not derived from an ancestor that confers novel activity. That idea sits at the core of our science. Our molecular glue degraders are opening new biological possibilities in treating disease, enabled by a team who laid much of the field’s groundwork.

Our Story

Humans possess roughly 20,000 proteins, but only a small fraction has been successfully targeted with therapeutics. Therefore, many disease-causing proteins still remain “undruggable.” Molecular glue degraders offer an opportunity to change that. By leveraging the cell’s built-in degradation machinery, these small-molecule medicines modify protein function—creating a neomorphic surface—to trap and ultimately eliminate problematic proteins in their entirety. Historically, however, identifying new molecular glues has been similar to stumbling through a dark room: slow, blind, and dependent on serendipitous discovery.

Neomorph is illuminating that process.

Using our next-generation discovery platform, molecular glue identification is no longer random chance. It allows for the discovery of thousands of high-confidence protein targets and multiple novel degrons, and the enablement of many E3 ligase systems. Entirely new systems, mechanisms, and therapeutic opportunities are now within our reach.

With an expansive clinical-stage pipeline across oncology, immunology, neurodegeneration, virology, cardiometabolic disease, and more—alongside multiple pharmaceutical partnerships—Neomorph is positioned to elucidate the gluable proteome at large.

Neomorph was founded in 2020 and is headquartered in San Diego, California.

The Meaning Within Our Mark

Our logo represents the same concept as our name: how molecular glues engineer a new or “neomorphic” surface and enable targeted protein degradation.

Leadership

Today, we are going even further: expanding beyond cereblon, uncovering new degrons, and unlocking high-confidence protein targets.

Our leadership team has spent more than a decade living and breathing molecular glue technology. Many of us previously worked together across industries and academia, publishing foundational research that helped set the field in motion. This includes seminal discoveries around cereblon—the most clinically validated E3 ligase in targeted protein degradation—which revealed how small molecules can selectively target proteins and opened the door to today’s molecular glue drugs.